Table 5.
Endpoints used in recent clinical trials of hospitalized influenza
| Drug | Clinicaltrials.gov identifier | Outcome measure |
|---|---|---|
| Baloxavir | NCT03684044 | Time to clinical improvement (hospital discharge or NEWS2 ≤ 2 for 24 h) |
| Danarixin | NCT02927431 | Time to clinical resolution (discharge or temp, O2 sat, and 2 of 3 RR, HR, SBP) |
| Flufenamic acid + clarithromycin | NCT03238612 | Mortality |
| IVIG | NCT02287467 | Day 7 ordinal scale |
| Oseltamivir (high v std) | NCT00298233 | % negative viral RNA day 5 |
| Peramivir | NCT00958776 | Time to clinical resolution (4 of 5) |
| Peramivir | NCT00957996 | Change viral titer in 48 h |
| Peramivir | NCT00453999 | Time to clinical resolution (4 of 5) |
| Peramivir | NCT02665351 | Change in influenza RNA load |
| Pimodivir | NCT03376321 | Day 6 ordinal scale—hospital recovery scale |
| Plasma | NCT02572817 | Day 7 ordinal scale |
| Plasma | NCT01052480 | Time to normalization of respiratory status (hypoxia and tachypnea) |
| Vis410 | NCT03040141 | Day 7 ordinal scale |
| Zanamivir | NCT01231620 | Time to clinical resolution (4 of the 5 vital signs [temp, O2 sat, RR, HR, SBP] or hospital discharge) |